Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
American Well Corporation stock logo
AMWL
American Well
$7.14
+2.3%
$7.75
$6.09
$12.95
$115.47M1.2858,832 shs46,377 shs
HeartBeam, Inc. stock logo
BEAT
HeartBeam
$1.12
-46.7%
$71.92
$1.17
$3.48
$38.77M-0.71123,886 shs118,715 shs
ImmunoPrecise Antibodies Ltd. stock logo
IPA
ImmunoPrecise Antibodies
$3.13
+19.0%
$1.65
$0.27
$3.20
$143.48M0.494.11 million shs2.71 million shs
MDxHealth SA stock logo
MDXH
MDxHealth
$3.23
+5.2%
$2.40
$1.35
$3.25
$152.75M1.4187,377 shs180,972 shs
Analysts Agree—These Gold Picks Outshine the Rest Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
American Well Corporation stock logo
AMWL
American Well
+1.53%-3.73%-14.15%-5.79%-21.01%
HeartBeam, Inc. stock logo
BEAT
HeartBeam
-2.59%-1.71%-14.43%-33.80%-51.51%
ImmunoPrecise Antibodies Ltd. stock logo
IPA
ImmunoPrecise Antibodies
-9.00%+30.20%+54.71%+372.09%+195.54%
MDxHealth SA stock logo
MDXH
MDxHealth
+4.78%+8.10%+26.86%+50.49%-6.12%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
American Well Corporation stock logo
AMWL
American Well
2.9185 of 5 stars
3.14.00.00.01.02.51.3
HeartBeam, Inc. stock logo
BEAT
HeartBeam
1.7704 of 5 stars
3.54.00.00.00.00.80.0
ImmunoPrecise Antibodies Ltd. stock logo
IPA
ImmunoPrecise Antibodies
2.3652 of 5 stars
3.53.00.00.02.50.00.6
MDxHealth SA stock logo
MDXH
MDxHealth
2.1696 of 5 stars
3.53.00.00.02.00.00.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
American Well Corporation stock logo
AMWL
American Well
2.14
Hold$9.1728.38% Upside
HeartBeam, Inc. stock logo
BEAT
HeartBeam
3.00
Buy$8.00617.49% Upside
ImmunoPrecise Antibodies Ltd. stock logo
IPA
ImmunoPrecise Antibodies
3.00
Buy$4.0027.80% Upside
MDxHealth SA stock logo
MDXH
MDxHealth
3.00
Buy$7.00116.72% Upside

Current Analyst Ratings Breakdown

Latest BEAT, MDXH, IPA, and AMWL Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/7/2025
American Well Corporation stock logo
AMWL
American Well
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$15.00 ➝ $12.00
7/17/2025
MDxHealth SA stock logo
MDXH
MDxHealth
Craig Hallum
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$8.00
5/23/2025
American Well Corporation stock logo
AMWL
American Well
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral$10.00 ➝ $8.00
(Data available from 8/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
American Well Corporation stock logo
AMWL
American Well
$254.36M0.45N/AN/A$18.24 per share0.39
HeartBeam, Inc. stock logo
BEAT
HeartBeam
N/AN/AN/AN/A$0.12 per shareN/A
ImmunoPrecise Antibodies Ltd. stock logo
IPA
ImmunoPrecise Antibodies
$17.59M8.21N/AN/A$0.37 per share8.46
MDxHealth SA stock logo
MDXH
MDxHealth
$90.05M1.70N/AN/A($0.02) per share-161.50
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
American Well Corporation stock logo
AMWL
American Well
-$208.14M-$8.07N/AN/AN/A-46.15%-41.99%-30.80%10/28/2025 (Estimated)
HeartBeam, Inc. stock logo
BEAT
HeartBeam
-$19.45M-$0.68N/AN/AN/A-447.96%-325.23%N/A
ImmunoPrecise Antibodies Ltd. stock logo
IPA
ImmunoPrecise Antibodies
-$21.69M-$0.68N/AN/AN/A-122.10%-40.62%-22.19%9/15/2025 (Estimated)
MDxHealth SA stock logo
MDXH
MDxHealth
-$38.07M-$0.88N/AN/AN/A-34.98%-374.98%-21.97%11/5/2025 (Estimated)

Latest BEAT, MDXH, IPA, and AMWL Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
9/15/2025Q1 2026
ImmunoPrecise Antibodies Ltd. stock logo
IPA
ImmunoPrecise Antibodies
-$0.04N/AN/AN/A$5.90 millionN/A
8/13/2025Q2 2025
HeartBeam, Inc. stock logo
BEAT
HeartBeam
N/A-$0.15N/A-$0.15N/AN/A
8/5/2025Q2 2025
American Well Corporation stock logo
AMWL
American Well
-$1.84-$1.24+$0.60-$1.24$63.87 million$70.90 million
8/5/2025Q2 2025
MDxHealth SA stock logo
MDXH
MDxHealth
-$0.13-$0.15-$0.02-$0.15$26.60 million$26.60 million
7/29/2025Q4 2025
ImmunoPrecise Antibodies Ltd. stock logo
IPA
ImmunoPrecise Antibodies
-$0.02-$0.04-$0.02-$0.04$7.89 million$5.06 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
American Well Corporation stock logo
AMWL
American Well
N/AN/AN/AN/AN/A
HeartBeam, Inc. stock logo
BEAT
HeartBeam
N/AN/AN/AN/AN/A
ImmunoPrecise Antibodies Ltd. stock logo
IPA
ImmunoPrecise Antibodies
N/AN/AN/AN/AN/A
MDxHealth SA stock logo
MDXH
MDxHealth
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
American Well Corporation stock logo
AMWL
American Well
N/A
3.29
3.27
HeartBeam, Inc. stock logo
BEAT
HeartBeam
N/A
2.98
2.98
ImmunoPrecise Antibodies Ltd. stock logo
IPA
ImmunoPrecise Antibodies
0.49
2.08
1.85
MDxHealth SA stock logo
MDXH
MDxHealth
13.81
1.31
1.92

Institutional Ownership

CompanyInstitutional Ownership
American Well Corporation stock logo
AMWL
American Well
56.05%
HeartBeam, Inc. stock logo
BEAT
HeartBeam
7.77%
ImmunoPrecise Antibodies Ltd. stock logo
IPA
ImmunoPrecise Antibodies
6.70%
MDxHealth SA stock logo
MDXH
MDxHealth
N/A

Insider Ownership

CompanyInsider Ownership
American Well Corporation stock logo
AMWL
American Well
11.82%
HeartBeam, Inc. stock logo
BEAT
HeartBeam
18.04%
ImmunoPrecise Antibodies Ltd. stock logo
IPA
ImmunoPrecise Antibodies
6.83%
MDxHealth SA stock logo
MDXH
MDxHealth
1.70%
CompanyEmployeesShares OutstandingFree FloatOptionable
American Well Corporation stock logo
AMWL
American Well
1,04016.15 million14.24 millionOptionable
HeartBeam, Inc. stock logo
BEAT
HeartBeam
1,70034.31 million28.12 millionNot Optionable
ImmunoPrecise Antibodies Ltd. stock logo
IPA
ImmunoPrecise Antibodies
8046.15 million43.00 millionNot Optionable
MDxHealth SA stock logo
MDXH
MDxHealth
30047.29 million46.48 millionNot Optionable

Recent News About These Companies

Insights Ahead: MDxHealth's Quarterly Earnings
Bio-Techne takes a hit on Exodx sale to Mdxhealth
MDxHealth CFO Kalfus Resigns
MDxHealth Q1 Revenues Leap 22 Percent
MDxHealth Reports Q1-2025 Results

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
American Well stock logo

American Well NYSE:AMWL

$7.14 +0.16 (+2.29%)
As of 03:47 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

American Well Corporation, an enterprise platform and software company, delivers digitally enabling hybrid care in the United States and internationally. The company offers Converge, a cloud-based platform that enables health providers, payers, and innovators to provide in-person, virtual and automated care; and delivers virtual primary care, post-discharge follow-up, chronic condition management, virtual nursing, e-sitting, on-demand and scheduled virtual visits, specialty consults, automated care, and behavioral health, as well as specialty care programs, including dermatology, musculoskeletal care, second opinion, and cardiometabolic care to patients and members. It provides Carepoint devices comprising carts, peripherals, tablets, and TVs, which serve as digital access points in clinical settings. In addition, the company offers Amwell Medical Group network services consisting of primary and urgent care, behavioral health therapy, acute psychiatry, lactation counseling, and nutrition services. Further, it provides professional services to facilitate implementation, workflow design, systems integration, and service expansion for its products, as well as patient and provider engagement services. The company sells its products through field sales professionals, channel partners, and value-added resellers. American Well Corporation was incorporated in 2006 and is headquartered in Boston, Massachusetts.

HeartBeam stock logo

HeartBeam NASDAQ:BEAT

BioTelemetry, Inc., a remote medical technology company, provides remote cardiac monitoring, remote blood glucose monitoring, centralized core laboratory services for clinical trials, and original equipment manufacturing services for healthcare and clinical research customers worldwide. It operates in two segments, Healthcare and Research. The Healthcare segment focuses on the remote cardiac monitoring to identify cardiac arrhythmias or heart rhythm disorders. This segment offers mobile cardiac telemetry services; and event monitoring services, which enable physicians to prescribe wireless event, digital loop event, memory loop event, memory loop event, and non-loop event monitors. It also provides traditional and extended Holter, pacemaker, international normalized ratio, implantable loop recorder, and other implantable cardiac device monitoring services. It serves cardiologists, electrophysiologists, neurologists, and primary care physicians. The Research segment offers laboratory services, such as cardiac monitoring, imaging, scientific consulting, and data management services for drug and medical device trials. Its centralized services comprise electrocardiogram, Holter monitoring, ambulatory blood pressure monitoring, echocardiography, multigated acquisition scan, imaging, protocol development, expert reporting, and statistical analysis. It also provides support services, such as project coordination, setup and management, equipment rental, data transfer, processing, analysis, and 24/7 customer support and site training. The company also focuses on manufacturing, testing, and marketing of cardiac devices and blood glucose monitoring devices, as well as offers contract manufacturing services. BioTelemetry, Inc. was founded in 1994 and is headquartered in Malvern, Pennsylvania.

ImmunoPrecise Antibodies stock logo

ImmunoPrecise Antibodies NASDAQ:IPA

$3.13 +0.50 (+19.01%)
As of 03:47 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, operates as a biotherapeutic research and technology company in Canada and internationally. It provides NonaVac DNA for complex protein classes, including GPCRs and ion channels; and Rapid Prime, a positive monoclonal antibodies for generating anti-idiotypic antibodies, and producing monoclonal antibodies against conformational epitopes. The company also offers syngeneic cell line for immunization and screening; and peptide production for subsequent antibody discovery campaign. In addition, it provides B cell select platform which allows for the interrogation of animal antibody repertoire; screening of the immune repertoire of rabbits and chickens and select the desired antibody directly from the B cells; single step hybridoma, a semi-solid media to grow mouse and rat hybridomas; and DeepDisplay, a combination of transgenic animal platform and custom IPA phage display antibody selection. The company also offers phage display, a custom immune libraries from multiple species; and CAR development, an adaptable antibody which allows the inclusion of functional data early in the screening funnel. Further, it provides silico developability, a profiling toolset for antibody lead candidates; and vitro analytical tools for the study of various critical quality attributes. Additionally, the company offers LucinaTech, an antibody humanization to identify essential framework and CDR residues; antibody affinity maturation for therapeutic and diagnostic application; and antibody chimerization for cloning and production of variable antibody domain. It also provides Eurofins preclinical services; hybrid service model, a service model designed to reduce time and risk with custom technologies and applications; and breadth and depth to accelerate assay development, screening cascades, drug candidate validation, and new biotherapeutic concepts. The company was incorporated in 1983 and is headquartered in Victoria, Canada.

MDxHealth stock logo

MDxHealth NASDAQ:MDXH

$3.23 +0.16 (+5.21%)
As of 03:45 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. Its testing solutions includes Select mdx, a non-invasive urine test for prostate cancer that measures the expression of two mRNA cancer-related biomarkers; Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; and Resolved mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection. The company offers genomic prostate score which provides personalized genomic insights to both physicians and patients navigating the complexities of prostate cancer diagnosis and treatment. It sells its products through urology sales force, consisting of direct sales representatives, strategic account managers, and regional sales managers. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was incorporated in 2003 and is headquartered in Herstal, Belgium.